Semaglutide tablets vs injections: which works better for weight loss?

You hate needles. Or you travel constantly. Here's where that changes the maths.

Picture this: you've read about Wegovy, you're a reasonable candidate, and then you realise it involves injecting yourself once a week for the foreseeable future. For some people, that's fine, the pen is small, the needle finer than a standard blood-test needle, and most find it unremarkable after the first couple of goes. For others, that single fact closes the door. The oral tablet exists partly for exactly that group.

The Wegovy tablet needs no pen, no sharps disposal, no cold chain on holiday. It sits at room temperature, travels without a cool bag, and asks only that you take it first thing in the morning before eating or drinking anything other than a small amount of plain water, then wait at least 30 minutes before breakfast. That's the practical trade-off: the tablet demands a daily morning ritual the injection doesn't. If your mornings are structured, that's manageable. If your schedule is genuinely unpredictable before 9am, the once-weekly injection may be the easier habit to build. If you're still weighing up whether semaglutide tablets or injections suit you better, that page walks through the practical and clinical considerations side by side. You can also read more about the tablet specifically on the Wegovy tablet overview page, which covers everything from the dosing schedule to storage.

Neither format is objectively more convenient for everyone. That's a personal-context question worth raising when you speak to a prescriber.

What the clinical trial numbers actually show, and what they don't

Both forms of semaglutide have phase-3 trial evidence behind them, but the trials weren't run head-to-head, so direct comparisons need care. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks: participants on 2.4mg weekly semaglutide lost around 15% of body weight on average. The OASIS 4 trial (307 adults, 64 weeks) tested the 25mg oral tablet: the average across all participants (regardless of how consistently they took it) was approximately 13.6%. Among those who adhered fully to the daily routine, the figure was around 17%.

That 17% figure is important context, but it carries a condition: it applies to people who didn't miss doses. Whether the gap between 13.6% and 15% reflects a true pharmacological difference or a real-world adherence difference is still being studied. Oral bioavailability for semaglutide is genuinely lower than the injection (the tablet contains an absorption enhancer (SNAC) to compensate) and the morning ritual exists precisely because food or other liquids block absorption sharply. The MHRA's 2026 approval of the 7.2mg Wegovy pen introduced an even higher injection dose, with trials showing approximately 20.7% average weight loss, narrowing the gap with tirzepatide. Where you'd sit in any of these distributions is something only a full clinical assessment can approximate.

Trial figures are population averages, not individual predictions. Sources: NEJM STEP 1; Novo Nordisk OASIS 4 data as reported at MHRA approval, June 2026; MHRA gov.uk news.

A quick check worth doing before you decide anything

Before you settle on a preference, spend 60 seconds looking at whether the pharmacy you're considering is registered with the GPhC, you can search the GPhC pharmacy register directly and find any legitimate online pharmacy by name or registration number. It takes less time than reading a social-media recommendation, and it tells you something that actually matters. Fake semaglutide pens are a documented problem in the UK (the MHRA has flagged large seizures of counterfeit weight-loss medicine) and sellers offering either form of semaglutide without a prescription are a red flag regardless of the price.

The tablet's novelty (the MHRA approved it in June 2026, making the UK the first in Europe to licence an oral GLP-1 for weight management) means some online sellers may claim to stock it before legitimate supply is established. If something seems off, it probably is. Our guide to sourcing Wegovy tablets in the UK covers what to look for. And if you want to understand the broader tablet-versus-injection question from another angle, the semaglutide tablets vs injection comparison goes into more depth on pharmacokinetics and real-world use.

Which suits you is a clinical decision, here's how ours works

Semaglutide tablets are not automatically the better or worse choice. They're a different format with a different daily ask, a slightly different evidence profile, and for some people a genuinely life-changing alternative to injections. For others, the weekly pen is simpler and the data at higher doses is stronger. Some patients who've been stable on the 2.4mg injection may move directly to the 25mg tablet under clinical guidance, that's not a decision to make alone.

At nume, every new consultation and every dose change is read by a named prescriber, not a screening algorithm. They look at your full health picture: BMI, weight-related conditions, any medicines you already take (oral contraceptives and the tablet's morning-routine requirement are both worth discussing), and what your day actually looks like. The clinical team brings that to every case. If you've looked at both options and still aren't sure, the effectiveness comparison and the injectable-versus-oral deep dive may help you form a clearer question to bring to your consultation. Which suits you is a clinical decision our prescribers make with you, not a choice the internet should make for you.

When you're ready, speak to our prescribers through a free consultation and get a same-day clinical review.